Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Not Recruiting

Trial ID: NCT01336803

Age - 10 Years-21 Years Condition - Bone Cancer, Bone - Osteosarcoma, Pediatric Radiology, Pediatric Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.

Official Title

Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Stanford Investigator(s)

Heike Daldrup-Link
Heike Daldrup-Link

Professor of Radiology (General Radiology) and, by courtesy, of Pediatrics (Hematology/Oncology)

Neyssa Marina

Eligibility


INCLUSION CRITERIA

   - Age 10 to 21 years

   - Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis

   - Informed consent with assent as appropriate.

EXCLUSION CRITERIA

   - Contraindication to MRI

   - Presence of metal implants

   - Need for sedation or anesthesia

   - Claustrophobia

   - Hemosiderosis or hemochromatosis

   - History of allergic reactions to similar compounds will be obtained and patients with
   positive history of allergic reactions will be excluded from the study

   - Females who are pregnancy or nursing

View More
View Less

Intervention(s):

drug: Feraheme

procedure: Magnetic Resonance Imaging (MRI) scan

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Brittney Williams
650-736-3688

New Trial Alerts

©2024 Stanford Medicine